Somatic mutation of Isocitrate dehydrogenase 1 (IDH1) at the locus of R132 (IDH1 (R132H)) occurs in > 70% of WHO grade II-III gliomas and secondary glioblastomas. To date it remains unknown whether the mutation is restricted to glial tumor cells. Microglial cells are the resident macrophages in the central nervous system. Tumor-infiltrating microglial cells/macrophages are major stromal cellular components of malignant gliomas and substantially contribute to the tumor mass. Differential identification of the IDH1 (R132H) mutant cellular components is of particular importance for understanding of the mutation-associated tumor biology. Here we discovered that a significant portion of CD68(+), Iba1(+), CX3CR1(+) microglial cells/macrophages also harbor the IDH1R132H mutation. The findings provide novel insights for understanding the mutation-associated tumor biology relevant to clinical applications as a predictive and/or prognostic marker or therapeutic target.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414408PMC
http://dx.doi.org/10.4161/cbt.20836DOI Listing

Publication Analysis

Top Keywords

isocitrate dehydrogenase
8
idh1 r132h
8
microglial cells/macrophages
8
cellular components
8
understanding mutation-associated
8
mutation-associated tumor
8
tumor biology
8
dehydrogenase 1r132h
4
mutation
4
1r132h mutation
4

Similar Publications

VASARI 2.0: a new updated MRI VASARI lexicon to predict grading and status in brain glioma.

Front Oncol

December 2024

NeuroRadiology Unit, Ospedale del Mare, Azienda Sanitaria Locale Napoli 1 Centro (ASL NA1 Centro), Naples, Italy.

Introduction: Precision medicine refers to managing brain tumors according to each patient's unique characteristics when it was realized that patients with the same type of tumor differ greatly in terms of survival, responsiveness to treatment, and toxicity of medication. Precision diagnostics can now be advanced through the establishment of imaging biomarkers, which necessitates quantitative image acquisition and processing. The VASARI (Visually AcceSAble Rembrandt Images) manual annotation methodology is an ideal and suitable way to determine the accurate association between genotype and imaging phenotype.

View Article and Find Full Text PDF

Study Question: Is elevated plasma molybdenum level associated with increased risk for idiopathic premature ovarian insufficiency (POI)?

Summary Answer: Elevated plasma molybdenum level is associated with an increased risk of idiopathic POI through vascular endothelial injury and inhibition of granulosa cell proliferation.

What Is Known Already: Excessive molybdenum exposure has been associated with ovarian oxidative stress in animals but its role in the development of POI remains unknown.

Study Design, Size, Duration: Case-control study of 30 women with idiopathic POI and 31 controls enrolled from August 2018 to May 2019.

View Article and Find Full Text PDF

Glioma is characterized by high heterogeneity and poor prognosis. Attempts have been made to understand its diversity in both genetic expressions and radiomic characteristics, while few integrated the two omics in predicting survival of glioma. This study was intended to investigate the connection between glioma imaging and genome, and examine its predictive value in glioma mortality risk and tumor immune microenvironment (TIME).

View Article and Find Full Text PDF

A series of novel isatin-oxime ether derivatives were designed, synthesized and characterized by H NMR and C NMR and HRMS. These compounds were evaluated for their in vitro cytotoxicity against three human cancer cell lines (A549, HepG2 and Hela) by MTT assay. According to the experimental results, compounds 6a (IC = 0.

View Article and Find Full Text PDF
Article Synopsis
  • GBM IDH wild type (GBM IDH wt) is linked to bad outcomes and intense inflammatory processes that help tumors grow and attract immune cells, making them more aggressive.
  • Researchers utilized RNA-seq and bioinformatics tools to explore how inflammatory molecules, specifically S100A proteins, play a role in glioma, finding a notable increase in S100A expression in GBM IDH wt compared to IDH mutants.
  • The study identified specific functions of S100A9, A11, and A13 in different regions of the glioma microenvironment, suggesting potential therapeutic strategies, such as using the RAGE inhibitor Azeliragon, currently in clinical trials, to counteract these inflammatory effects.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!